Anti-tumor effects of an Id antagonist with no acquired resistance
P. M. Wojnarowicz, M. G. Escalono, Y.-H. Huang, B. Desai, Y. Chin, R. Shah, S. Xu, O. Ouerfelli, R. K. Soni, J. Philip, D. C. Montrose, J. H. Healey, V. K. Rajasekhar, W. A. Garland, L. Norton, , R. Benezra
This study demonstrates that AGX51, an Id antagonist, effectively inhibits tumor growth in multiple cancer models without inducing acquired resistance.
bioRxiv · Jan 6, 2020 · PreprintCancer Biology